Keith Ablow, M.D.

Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs. The company’s first product is the Lumicell Direct Visualization System, designed to provide real-time illumination of cancerous tissue within the breast cavity during the initial lumpectomy, potentially reducing repeat surgeries. Lumicell’s proprietary, pan-oncologic optical imaging agent is also being explored across a wide variety of solid tumor indications. The company aims to enhance the standard of care treatment by guiding the resection of additional cancer that may have otherwise been left behind.

Ourly is the responsible way to transfer money from parents to kids. Visit us at Ourly.com to find out why.

G2 Investment Group is an independent, privately‐owned financial services firm that is engaged in investment management, advisory, private capital raising and other capital markets activities. G2 was established in 2008 by J. Todd Morley and partners amid the fallout from the global financial crisis and massive deleveraging that ensued. Previously, Mr. Morley co-founded Guggenheim Partners, an investment management company with more than $140 billion in assets under supervision.

Tory Burch is an American luxury lifestyle brand founded in New York in 2004. What began with a boutique in Manhattan and an e-commerce site has since grown into a global business with more than 370 stores across North America, Europe, the Middle East, Latin America, Asia and Australia. In addition, the brand is available at more than 3,000 department and specialty stores worldwide. Tory’s design philosophy is defined by effortless silhouettes, innovative materials, eclectic juxtapositions of color, and the tension of past and present. Her collections include ready-to-wear, handbags, footwear, accessories, jewelry, home and beauty. Empowering women is Tory’s guiding principle, expressed through her collections and her work at the Tory Burch Foundation. Established in 2009, the Foundation provides women entrepreneurs in the United States with capital, education, and community. Every Tory Burch product supports the Foundation’s work to empower women. Through her unique hybrid model, Tory has created a paradigm for authentic brand purpose. Tory has been recognized with numerous awards and honors, including the CFDA for Accessory Designer of the Year, Harper’s Bazaar’s Designer of the Year, the Parsons School of Design’s Table Award, the Wharton School’s Jay H. Baker Retailing Center’s Retail Excellence Award, the Breast Cancer Research Foundation’s Sandra Taub Humanitarian Award, Forbes’s Most Powerful Women in the World, and Glamour’s Women of the Year. Her first book, Tory Burch In Color (Abrams, 2014), was a New York Times Best Seller, and her designs have been featured in the Metropolitan Museum of Art’s Costume Institute.

Guggenheim Partners is a global investment and advisory firm. We help governments, institutions, and individuals through two primary businesses. To learn more about these businesses, please follow their respective LinkedIn pages. Guggenheim Investments: A premier asset manager and investment advisor. (https://www.linkedin.com/company/guggenheim-investments) Guggenheim Securities : A full-service investment banking and capital markets firm. (https://www.linkedin.com/company/guggenheim-securities)

Louder.ai is the worlds first crowdfunded ad platform, allowing individuals to "Ad" Their Voice for causes, campaigns and candidates they support.

#HELP22 (www.help22.org) was founded by Dr. Keith Ablow, Commander Kirk Lippold, USN Ret and Christian Josi to combat the epidemic of suicide amongst our nations veterans. OUR MISSION: The purpose of #HELP22 is to reinforce the will to live among our veterans and military service members through coaching, counseling, and mentoring. OUR VISION: Our vision is to reduce the approximately 22 suicides per day among veterans without charging any veteran for our efforts. It is to use insight, empathy and energy to kindle hope. WHAT IS #HELP22? #HELP22 is a network of volunteers skilled in listening who offer their assistance to veterans free of charge. They proactively impart hopeful, inspirational messaging to fuel resiliency. WHAT #HELP22 IS NOT: #HELP22 is not a crisis organization and does not function in any emergency capacity. We attempt to prevent such cases by active listening and motivational communications to veterans on an ongoing basis. READ MORE . . . https://www.pain-2-power.com/dr-keith-ablow-and-commander-kirk-lippold-usn-ret-launch-effort-to-curb-veteran-suicides/

A bespoke 1:1 consulting/coaching service with New York Times bestselling Dr. Keith Ablow. Dr. Ablow has worked with Fortune 500 CEOs, founders, entrepreneurs, professional athletes and noted political figures (including Presidential Cabinet members) to increase their clarity of thought, momentum, vision and success. Dr. Ablow has appeared over 1000 times on national broadcasts, including the Today Show, Good Morning America, Fox & Friends, CBS This Morning, 20/20, Inside Edition and a host of other programs. His writings have been published by The Washington Post, USA Today, the New York Times, the New York Post and many other newspapers and magazines.

We are an elite intelligence and security firm composed of highly-trained intelligence analysts, operations specialists, cybersecurity experts, and business leaders. We customize strategies and operations to collect, generate, and analyze intelligence to protect our clients and their families, companies, and interests worldwide.

Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs. The company’s first product is the Lumicell Direct Visualization System, designed to provide real-time illumination of cancerous tissue within the breast cavity during the initial lumpectomy, potentially reducing repeat surgeries. Lumicell’s proprietary, pan-oncologic optical imaging agent is also being explored across a wide variety of solid tumor indications. The company aims to enhance the standard of care treatment by guiding the resection of additional cancer that may have otherwise been left behind.